Form 4: Arvinas Director Briggs Morrison Receives Significant Equity Grants

Arvinas, Inc. Director Briggs Morrison was granted 16,025 restricted stock units and 23,105 stock options on June 25, 2025, as part of his compensation.

Summary

• Briggs Morrison, a Director of Arvinas, Inc. (ARVN), was granted 16,025 Restricted Stock Units (RSUs) on June 25, 2025.
• Each RSU represents a contingent right to receive one share of Arvinas' common stock upon settlement for no consideration.
• The RSUs are set to vest in full on the earlier of June 25, 2026, or the first meeting of the board of directors held after the following annual meeting of stockholders, contingent on Mr. Morrison's continued service.
• Mr. Morrison also received a grant of 23,105 stock options on June 25, 2025, with an exercise price of $7.8 per share.
• These stock options will vest in full on the earlier of June 25, 2026, or the first meeting of the board of directors held after the following annual meeting of stockholders, also subject to his continued service.
• The stock options have an expiration date of June 24, 2035.
• Following these transactions, Mr. Morrison beneficially owns 46,021 shares of common stock directly and 23,105 derivative securities (stock options) directly.

Sentiment

Score: 7

Explanation: The document reports a standard equity compensation event for a director, which is generally viewed positively as it aligns management interests with shareholders. There are no negative financial implications or red flags indicated by this specific filing.

Positives

• The equity grants align the director's financial interests with those of the shareholders, incentivizing long-term value creation.
• The grants are a standard component of director compensation, reflecting ongoing commitment and service to the company.

Negatives

• The grants represent potential future dilution for existing shareholders upon vesting and exercise, although this is a common aspect of equity compensation plans.

Risks

• The vesting of both the RSUs and stock options is subject to Briggs Morrison's continued service with Arvinas, Inc. until the vesting date.

Future Outlook

The vesting schedules for the RSUs and stock options indicate an expectation of continued service from Director Briggs Morrison through at least June 25, 2026, or the first board meeting after the next annual stockholders' meeting.

Industry Context

Equity grants, including Restricted Stock Units and stock options, are a common and widely accepted form of compensation for directors and executives in the biotechnology and pharmaceutical industries. This practice aims to align the interests of company leadership with those of shareholders, encouraging long-term growth and performance.

Comparison to Industry Standards

• Equity grants to directors are a common form of compensation in the biotechnology industry, aligning director interests with shareholder value.
• The specific terms, including the vesting schedule and the grant of both RSUs and stock options, are typical for such awards in the sector, reflecting standard corporate governance practices for incentivizing board members.

Stakeholder Impact

• Shareholders: The grants align the director's interests with shareholder value, potentially leading to better long-term performance. However, they also represent potential future dilution upon vesting and exercise.
• Employees: No direct impact mentioned.
• Customers: No direct impact mentioned.
• Suppliers: No direct impact mentioned.
• Creditors: No direct impact mentioned.

Next Steps

• Vesting of the 16,025 Restricted Stock Units on the earlier of June 25, 2026, or the first board meeting after the following annual meeting of stockholders.
• Vesting of the 23,105 Stock Options on the earlier of June 25, 2026, or the first board meeting after the following annual meeting of stockholders.
• Potential exercise of stock options by Briggs Morrison prior to their expiration on June 24, 2035.

Key Dates

Keywords

ARVINAS, ARVN, SEC Form 4, Insider Transaction, Equity Grant, Restricted Stock Units, Stock Options, Director Compensation, Corporate Governance, Biotechnology